General
Preferred name
DOBUTAMINE
Synonyms
DOBUTAMINE HYDROCHLORIDE ()
LEVDOBUTAMINE ()
Dobutamine (hydrochloride) ()
DOBUTAMINE LACTOBIONATE ()
46236 ()
NSC-299583 ()
Dobutamine hcl ()
Posiject ()
Dl-dobutamine hydrochloride ()
Dobutrex ()
Compound 81929 ()
COMPOUND-81929 ()
Racemic dobutamine ()
Dl-dobutamine ()
LY207506 ()
LY-207506 ()
P&D ID
PD009695
CAS
49745-95-1
34368-04-2
74753-15-4
104564-71-8
Tags
drug candidate
natural product
drug
available
Approved by
FDA
First approval
1978
Drug Status
approved
Drug indication
Heart failure
Cardiotonic
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine.
INDICATION Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
DESCRIPTION Dobutamine is a β-adrenergic receptor agonist. (GtoPdb)
DESCRIPTION Selective 5-HT2A antagonist (Tocris Bioactive Compound Library)
DESCRIPTION alpha1, beta1 and beta2 agonist (Tocriscreen Plus)
DESCRIPTION beta1 Adrenoceptor agonist (LOPAC library)
DESCRIPTION α1, β1 and β2 agonist (Tocriscreen Total)
Cell lines
0
Organisms
3
Compound Sets
29
AdooQ Bioactive Compound Library
A10325
Cayman Chemical Bioactives
15582
ChEMBL Approved Drugs
CHEMBL1200418
CHEMBL926
ChEMBL Drugs
CHEMBL1200418
CHEMBL926
CHEMBL4297079
Concise Guide to Pharmacology 2017/18
535
Concise Guide to Pharmacology 2019/20
535
Concise Guide to Pharmacology 2021/22
535
Concise Guide to Pharmacology 2023/24
535
Drug Repurposing Hub
DrugBank
DB00841
DrugBank Approved Drugs
DB00841
DrugCentral
937
DrugCentral Approved Drugs
937
DrugMAP
DMD1B8Z
DrugMAP Approved Drugs
DMD1B8Z
DrugMatrix
Guide to Pharmacology
535
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1200418
CHEMBL926
MedChem Express Bioactive Compound Library
HY-15746
NCATS Inxight Approved Drugs
3S12J47372
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T8149
The Spectrum Collection
Tocris Bioactive Compound Library
0515
Tocriscreen Plus
0515
Tocriscreen Total
External IDs
60
Properties
(calculated by RDKit )
Molecular Weight
301.17
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
2
cLogP
2.96
TPSA
72.72
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.59
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Selectivity
beta1
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
Adrenergic Receptor
ADRB1, ADRB2
Primary Target
Non-selective Adrenergic ? Receptors
MOA
Agonist
Adrenergic Receptor agonist
Indication
congestive heart failure
Therapeutic Class
Cardiotonic Agents
Source data